Clinical Trial Regulatory Affairs Services
Regulatory Affairs Support for Phase I, Phase II and Phase III Clinical Trials
TCR-Solutions provides clinical trial regulatory affairs services for Phase I, Phase II, and Phase III clinical trials across the UK, EU, and global markets. As a UK CRO with global reach, we support sponsors with regulatory strategy and submissions designed to keep studies moving efficiently from start-up through to ongoing delivery.
Our role is to ensure that clinical trial regulatory strategy supports submission readiness and timely study start-up, rather than becoming a barrier to activation.
Our Clinical Trial Regulatory Affairs Services Include
- MHRA Combined Review (CTA) and IRAS submissions for UK trials
- EU Clinical Trial Regulation (CTR) submissions via CTIS
- FDA IND preparation and submission support
- IMPD preparation and lifecycle management
- Ethics committee and HRA approvals
- Substantial amendments and safety reporting
We work closely with Clinical Trial Project Management and Clinical Trial Site Setup teams to ensure regulatory timelines are aligned with operational delivery.
Why Regulatory Affairs Matters in Clinical Trials
Regulatory approvals are a critical part of the timelines in all Phase I, Phase II and Phase III clinical trials.
Delays in regulatory submissions or approvals can lead to:
• Delayed site activation and recruitment
• Missed development milestones
• Increased costs
A strong regulatory affairs approach helps reduce avoidable delays, minimise queries from authorities and support more predictable study delivery across jurisdictions. At TCR-Solutions, we take a proactive approach to clinical trial regulatory strategy, ensuring:
• Submissions are complete, accurate, and aligned with expectations
• Queries are minimised through strong preparation and document quality
• Timelines are managed in line with operational milestones
We integrate regulatory strategy with study delivery rather than treating it as a standalone function.
This ensures that regulatory planning supports site activation, recruitment, and overall study timelines across Phase I, Phase II and Phase III clinical trials.
By linking regulatory strategy, project management and site setup, we provide a joined-up approach that supports efficient study start-up and ongoing trial progression in the UK and internationally.
Frequently Asked Questions
Do you support global regulatory submissions for clinical trials?
Yes — we support clinical trial regulatory affairs services across the UK, EU, and global markets, including regulatory strategies for multinational clinical studies.
Do you support regulatory activities for Phase III trials?
Yes — we support regulatory affairs support across Phase I, Phase II and Phase III clinical trials.
What is included in your clinical trial regulatory affairs services?
Our services include UK and EU submissions, FDA IND support, IMPD preparation, ethics and HRA approvals, substantial amendments and regulatory lifecycle support.